EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Role of C-Reactive Protein in Kidney Diseases

Jiaxiao Li, Junzhe Chen, Hui-Yao Lan, Ying Tang

Kidney Diseases · 2023 · 9 (2) · 73-81

DOI: 10.1159/000528693 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney Diseases, online erschienen am 14.12.2022. Verfasst von Jiaxiao Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: C-reactive protein (CRP) is an acute-phase protein and has been found to be a risk factor for acute kidney injury (AKI) and chronic kidney diseases (CKD). However, the role and mechanisms of CRP in AKI and CKD remain largely unclear. Summary: Clinically, elevated serum CRP is a risk factor or biomarker for patients with AKI and CKD. Interestingly, in critically ill COVID-19 patients, increased serum CRP is also associated with the development of AKI. Functionally, studies using human CRP transgenic mouse models find that CRP is pathogenic and can function as a mediator for AKI and CKD as mice overexpressing human CRP promote AKI and CKD. Mechanistically, CRP can promote AKI and CKD via NF-κB and Smad3-dependent mechanisms. We found that CRP can activate Smad3 signaling directly and cause AKI via the Smad3-p27-dependent G1 cell cycle arrest mechanism. Thus, targeting CRP-Smad3 signaling with a neutralizing antibody or Smad3 inhibitor can inhibit AKI. Key Messages: CRP acts not only as a biomarker but also as a mediator for AKI and CKD. CRP can activate Smad3 to induce cell death and cause progressive renal fibrosis. Thus, targeting CRP-Smad3 signaling may represent a promising therapy for AKI and CKD.

Schlagwörter

Stichwörter der Autor:innen

Acute kidney injuryC-reactive proteinCD32Diabetic nephropathyUUO

Autor:innen und Institutionen

  • Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China.
  • Departments of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, and Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong, China.

Zitieren

APA

Li, J., Chen, J., Lan, H. Y., & Tang, Y. (2023). Role of C-Reactive Protein in Kidney Diseases. Kidney Diseases, 9(2), 73-81. https://doi.org/10.1159/000528693

Vancouver

Li J, Chen J, Lan HY, Tang Y. Role of C-Reactive Protein in Kidney Diseases. Kidney Diseases. 2023;9(2):73-81. doi:10.1159/000528693

BibTeX
@article{Li2023,
  author = {Li, Jiaxiao and Chen, Junzhe and Lan, Hui-Yao and Tang, Ying},
  title = {Role of C-Reactive Protein in Kidney Diseases},
  journal = {Kidney Diseases},
  year = {2023},
  volume = {9},
  number = {2},
  pages = {73--81},
  doi = {10.1159/000528693}
}
Kostenlos starten →